Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OREX
Nice couple of days here.
6.03 AH
Looking for a big move up next week.
OREX
Moving on up!
yes,
very nice and I predict it will continue to climb into earnings in March, IMO.
Very nice price action here
OREX
Up for EU approval soon. Preliminary vote was in favor of approval by 31-1 margin.
Already FDA approved with a great launch that is ahead of expectations.
This should go way up from here after recent pullback, IMHO!
OREX
...In December 2014, the Committee for Medicinal Products for Human Use (CHMP), the centralized expert advisory committee of the European Medicines Agency, adopted a positive opinion and recommended that the European Commission (EC) grant a centralized marketing authorization through a binding EC decision. The CHMP last week released minutes from their December meeting stating that the positive opinion for Mysimba was adopted by a majority vote with 31 member states in favor and two opposed.
This looks extremely good for approval in Europe in March.
I'm out at 4.20 from entry at 3.73
Will look to re-enter lower.
Good luck to all longs here!
Earnings data in about a month.
Should be above initial projections IMO.
Looks like a very successful launch by all accounts.
OREX
Orexigen Therapeutics to Speak at the Leerink Global Healthcare Conference
2 days 14 hours 29 minutes ago - DJNF
SAN DIEGO, Feb. 6, 2015 /PRNewswire/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced that management will participate in a fireside chat discussion at the Leerink Global Healthcare Conference in New York. The discussion is scheduled for Thursday, February 12(th) at 1:00 p.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investors section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
Orexigen Contact: Media Contact:
McDavid Stilwell David Walsey
VP, Corporate Communications and Business Development BrewLife
(858) 875-8629 (858) 617-0772
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orexigen-therapeutics-to-speak-at-the-leerink-global-healthcare-conference-300032362.html
I'm hanging on too. Actually accumulating as I can on dips.
This is way oversold and the eventual bounce should be a thing of beauty, IMHO
I know
It's great. Contrave sales are above projections.
This is only going higher!
JMHO
Yes
Already got the nod from their committee.
This will be the only weight loss pill in Europe.
US sales are ahead of schedule around 6,000 scrips per week so far.
Very successful launch.
nice pop this AM on outperform news.
OREX
up this AM on upgrade news.
Nice pop
From Motley Fool:
Orexigen and its marketing partner Takeda are attempting to finally open up the massive weight loss market that their competitors, Arena Pharmaceuticals and VIVUS, have so far failed to capture with their respective diet pills.
Despite tens of millions of severely obese potential patients within the U.S., Arena and VIVUS' FDA approved weight loss drugs, Belviq and Qsymia, will probably generate only about $100 million in combined sales this year.
Orexigen's pill, Contrave, has two advantages over its competitors that are already paying dividends in terms of capturing market share. First, Contrave is the only FDA approved obesity drug with a large amount of data on cardiovascular outcomes. Interim analysis from the so-called "Light Study", which is onoing and won't report final results until 2017, was good enough for the FDA to approve the drug and European regulators to recommend approval. Neither Belviq nor Qsymia appear to be on track to gain approval in Europe anytime soon, largely due to outstanding questions regarding their cardiovascular safety profiles.
The second advantage Contrave has is that Takeda has put a huge amount of marketing muscle behind its commercial launch, with a reported 900 sales reps dedicated to the U.S. market. This effort dwarfs the marketing power behind either Belviq or Qsymia.
Contrave should gain European approval by the second-quarter of 2015, and Orexigen looks poised to take the lion's share of the obesity market going forward, making it a stock to keep an eye on next year.
Orexigen Therapeutics Started at Outperform by RBC >OREX
Thursday 01/22/2015 04:57 PM ET - Foreign Wire via Dow Jones News
Foreign Wire via Dow Jones News has only provided a headline at this time.
OREX
Orexigen Therapeutics Started at Outperform by RBC >OREX
Thursday 01/22/2015 04:57 PM ET - Foreign Wire via Dow Jones News
Foreign Wire via Dow Jones News has only provided a headline at this time.
OREX
Great price for entry at $5.20
I have to think this will climb in anticipation of Contrave sales numbers to be reported in March.
Analysts predicting $9 by EOY.
BTW I Recently sold my CRMMF that I tried. To tell you and Sheff about for $1.80 from average price of .27 for a huge gain.
GLTY
OREX
Great entry point here IMO
Contrave sales will push this higher into first quarter numbers.
IMHO, of course.
FDA-approved weight loss pill in the best market in the world!
900 Takeda reps already detailing to docs.
It's ok
It's just a buying opportunity IMO. It's an FDA approved weight loss pill. One of the best markets in the world.
Contrave sales will push this!
Should climb into first Q sales.
All IMHO of course
They brought the price down without any bad news.
CEO said great things about the launch.
This is typical. I bought more on the dip.
OREX
company overview at the J.P. Morgan 2015 Healthcare Conference in San Francisco tomorrow morning should be interesting
OREX
SAN DIEGO, Jan. 8, 2015 /PRNewswire/ --
Orexigen® Therapeutics, Inc. (OREX) today announced that management will present a company overview at the J.P. Morgan 2015 Healthcare Conference in San Francisco. The presentation is scheduled for Tuesday, January 13, at 8:00 a.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investors section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
Investor Contact
McDavid Stilwell
VP, Corporate Communications and Business Development
(858) 875-8629
SAN DIEGO, Jan. 8, 2015 /PRNewswire/ -- Orexigen®
Therapeutics, Inc. (OREX) today announced that management will present a company overview at the J.P. Morgan 2015 Healthcare Conference in San Francisco. The presentation is scheduled for Tuesday, January 13, at 8:00 a.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investors section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
Investor Contact
McDavid Stilwell
VP, Corporate Communications and Business Development
(858) 875-8629
I bought more today
OREX
First Q should be big here.
U.S. Contrave sales coming on line and 800 Takeda reps pushing it.
GLTA
great testamonial!!
Now we just need for the FDA to allow it as an option to more invasive bariatric procedures.
Do the right thing FDA!!
just bought back in at 31.50 during the afternoon sell off.
Looking forward to the bounce early January.
Guys,
This is not a trade. It's an investment!
New Year's resolutions should be good for Contrave sales IMO.
OREX
pulled back after good news.
Makes no sense to me. Could it be end of the year funds rebalancing?
I don't know, but it looks like an opportunity for shorts to cover down here.
I just bought some more.
I just bought some more also.
seems like a great opportunity for shorts to start covering down here.
Lol, you are correct!
I took the opportunity to buy more today.
IMO, you can't hold down, what should be the gold standard in Hep C treatment, for very long.
One pill, once per day for a cure. No Riboviron and very good side effect profile.
The market will wait on sales numbers in February.
We should see shorts starting to cover today.
As they bail, the price should get back to 6.80's IMO.
$7's should not be too far off. IMO
AR is Antero
Oil and gas play
OREX is consolidating today at new floor of around 6.50's
insiders and institutions hold about 90% of the shares so need to play with the other 10% of the float for now.
Once it consolidates here for a bit, it will move north again in my opinion.
I still like my PT of $12 in the next two quarters.
yes,
but the difference here is that it is already commercially available in the U.S. with active sales going on as we speak.
Takeda sales force of 800 reps already detailing docs.
This is not the same paradigm.
I really like that "across the globe" part!
it's usually very good to have great news come out when the market is already primed to have a good day.
The overall market is green. We should see it go over $7 today IMO.
I like my price target of $12
it's already selling in the states. Now the EU approval should take the brakes off this thing.
I like my price my price target of $12
We should see it go over $7 today IMO